Moleculin Biotech, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $12.8 million, compared to a net loss of $5.9 million for the same period in 2025. The company did not generate any revenue during this quarter, maintaining a consistent trend from the previous year. Operating expenses increased to $7.9 million from $5.9 million, primarily driven by a rise in research and development costs, which surged to $5.4 million from $3.4 million, reflecting ongoing clinical trials, particularly the pivotal Phase 2B/3 trial of Annamycin for relapsed/refractory acute myeloid leukemia (AML).
The company’s total assets grew to $23.4 million as of March 31, 2026, up from $22.1 million at the end of 2025. Cash and cash equivalents increased to $10.3 million from $8.9 million, bolstered by financing activities that generated approximately $7.6 million in the first quarter. This included proceeds from the exercise of warrants and sales under an at-the-market equity program. However, the accumulated deficit rose to $218.8 million, highlighting the ongoing financial challenges faced by the company as it continues to invest heavily in its clinical programs without generating revenue.
In terms of strategic developments, Moleculin announced the closure of its Australian subsidiary, Moleculin Australia Pty. Ltd., in April 2026, aimed at reducing corporate overhead costs. The company is focusing its resources on the MIRACLE trial, which is expected to provide interim data in mid-2026. Additionally, the company has made significant progress in its clinical trials, with preliminary data indicating a composite complete remission rate exceeding 40% for Annamycin in the MIRACLE trial, which is a positive indicator for its potential efficacy.
Operationally, the company has seen an increase in its common stock outstanding, rising to 5,336,350 shares as of May 7, 2026, from 3,199,228 shares at the end of 2025. This increase is attributed to warrant exercises and stock sales under the equity program. The company continues to seek additional funding to support its operations, with management indicating a need for approximately $25 million to sustain its clinical development and operational activities into early 2027.
Looking ahead, Moleculin remains focused on advancing its lead drug candidate, Annamycin, through ongoing clinical trials and is optimistic about the upcoming data readouts. However, the company acknowledges the need for substantial additional financing to continue its operations and achieve profitability. The management's forward-looking statements emphasize the importance of securing funding through various means, including equity offerings and strategic partnerships, to support its ambitious clinical development plans.
About Moleculin Biotech, Inc.
Moleculin Biotech is a late-stage pharmaceutical company focused on developing innovative cancer therapies. Its lead drug, Annamycin, is a non-cardiotoxic anthracycline targeting relapsed/refractory AML and lung metastases, with potential applications in hard-to-treat cancers. The company advances its portfolio through clinical trials, leveraging proprietary lipid technology and collaborations with academic institutions to address unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.